Related Experiment Videos
Blood profile during and after hemoglobin substitute administration
X M Mueller1, H T Tevaearai, J P Gardaz
1Clinic for Cardiovascular Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
The International Journal of Artificial Organs
|March 31, 2000
Summary
Diaspirin Crosslinked Hemoglobin (DCLHb) showed good hematological tolerance in calves, with no organ deposits. This blood substitute demonstrated a prolonged plasma expander effect over seven days.
Area of Science:
- Biomedical Engineering
- Hematology
- Toxicology
Background:
- The in vivo effects of Diaspirin Crosslinked Hemoglobin (DCLHb) on hematology and biochemistry require investigation.
- Understanding the safety and efficacy of novel blood substitutes is crucial for clinical applications.
Purpose of the Study:
- To evaluate the hematological and biochemical effects of DCLHb in a calf model.
- To assess the safety profile of DCLHb, including organ deposition and plasma expander effects.
Main Methods:
- Six calves underwent a 5-hour isovolemic hemodilution with either DCLHb or hydroxyethyl starch (Haes).
- Blood samples were collected hourly during perfusion and at postoperative days 1, 2, and 7.
- Hematological parameters, biochemistry, and postmortem organ analysis were performed.
Main Results:
- Blood cell profiles remained similar between DCLHb and Haes groups.
- Peak methemoglobinemia reached 4.2% in the DCLHb group.
- DCLHb administration resulted in significantly higher osmolarity, particularly on postoperative days 1 and 2, with no observed hemoglobin deposits in major organs.
Conclusions:
- DCLHb exhibits good hematological tolerance and a prolonged plasma expander effect in large quantities.
- The study supports the potential for DCLHb as a safe blood substitute with no major organ deposition.
- Further research is warranted to fully elucidate the biochemical impacts and long-term effects.